Moderna, which has been studying lower-dose versions to help stretch supplies of its vaccine, has been delivering an approved 100-microgram dose to date.The drugmaker has said early booster shot data for a 50-microgram version showed it helped protect against emerging virus variants.
Lower doses may also be given to children who may not require a full one.Combined with a previous deal with Spain's Rovi, Moderna's pact with Lonza brings 50-microgram production in Europe to up to 600 million doses annually, with the capacity due to come on-line this year.Pfizer's and BioNTech's mRNA shot has been approved for 12-15-year-olds in Europe and the United States, and Moderna is aiming for approval for teens as data showed its shot has been found.